Roche has launched Elecsys® HBeAg quant, an immunoassay for the qualitative and quantitative determination of hepatitis B e antigen (HBeAg) in human serum and plasma.

This launch means that, in combination with other laboratory results and clinical information, patients can now receive confirmation of whether they have hepatitis B (HBV) and, if so, to what extent, as well as treatment monitoring through a single assay. It is intended for use on cobas® e analysers in CE-marked countries.

The Elecsys HBeAg quant reduces complexity and improves operational efficiency by streamlining workflow for laboratory staff, and can simplify the patient experience. It can also be used as a tool in perinatal screening and to monitor antiviral treatment response in infected patients, potentially supporting the implementation of a therapeutic plan tailored to the individual patient’s needs.

Hepatitis B affects millions of people each year and is a major global health burden. The launch of the Elecsys® HBeAg quant immunoassay underscores Roche’s commitment to addressing healthcare’s greatest challenges in support of clinicians and their patients,” said Matt Sause, CEO of Roche Diagnostics.

To view the source version, please click HERE.

en_GBEnglish (UK)